PATENT CLAIM ANALYSIS

Application Number: 15950707
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "170000"]

Abstract:
Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

Claim (Index 16):
The method according to  claim 11 , comprising administering about 200 mg/day of the niraparib to the patient.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.75758
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13034340', '14607732', '15551708', '15852551', '15337274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6971419488893901
- 35 USC 102 Novelty (BERT): 0.5252018388777498
- Combined Prediction Score: 0.679947937888226
- Mean Citation Score: 276.71241000000003
- Max Citation Score: 306.766
- Similarity Product: 222.8023176832199

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test